Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848689 · ClinicalTrials.gov registry record
FQ Restriction for the Prevention of CDI
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 5,871
- Enrollment target
NCT03848689 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 5,871 participants.
The verdict
NCT03848689 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 5,871 participants
- Enrollment target
Study Summary
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs). The investigators will model a successful FQ PPA strategy in several Wisconsin ICUs and compare whether the intervention has improved outcomes in reducing CDIs. An additional goal of the study is to evaluate environmental and work system factors using systems engineering models in order to determine the most successful way to implement these new strategies.
Interventions
- OTHER Control
- OTHER fluoroquinolone preprescription authorization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,871 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2024-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03848689
The ClinicalTrials.gov registry entry for NCT03848689 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,871 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03848689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03848689 about?
NCT03848689 is a clinical study titled "FQ Restriction for the Prevention of CDI". This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs). The investigators will model a successful FQ PPA strategy in several W...
What is the current status of trial NCT03848689?
This trial is currently completed. The enrollment target is 5,871 participants. The study started on 2019-05-01. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT03848689?
The interventions under investigation include: Control (OTHER), fluoroquinolone preprescription authorization (OTHER).
Who is sponsoring clinical trial NCT03848689?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.